Using cutting-edge SMGT-GLP-1 technology, the patch delivers active ingredients deep into the skin to regulate insulin, suppress glucagon, and slow gastric emptyingsupporting healthy weight loss
and EU product information emphasise gastrointestinal adverse reactions (nausea, vomiting, diarrhoea, constipation, abdominal pain) as common with semaglutide, especially around dose escalation
[12] [13] Readers should note that final peer-reviewed results from this programme are still emerging, and specific percentage figures may change as the full dataset is published
Front-line clinicians must inform and drive the design of care, but the systems of care should be held accountable for implementation
GLP-1 agonists did not show a significant effect, with an SMD of 0.67 (95% CI: 2.02 to 0.68, p = 0.33)
A Sharps Container: Professionalism and safety demand a proper place to dispose of used needles